Literature DB >> 11509677

The role of macrophages in glomerulonephritis.

D J Nikolic-Paterson1, R C Atkins.   

Abstract

Macrophage accumulation is a prominent feature in most types of human glomerulonephritis. In particular, tubulointerstitial macrophage accumulation correlates with the degree of renal dysfunction and is predictive of disease progression. Depletion studies have shown that macrophages can induce glomerular injury in experimental glomerulonephritis. Moreover, recent studies targeting chemokines and adhesion molecules have shown that inhibiting macrophage accumulation can suppress progressive renal injury in animal models of glomerulonephritis. Macrophages can produce many molecules with the potential to cause renal damage, although the precise mechanism(s) of macrophage-mediated renal injury have yet to be determined. It is now evident that tubules-a major source of chemokines and adhesion molecules-play an active role in promoting interstitial macrophage infiltration and activation. Thus, targeting pro-inflammatory functions of tubular epithelial cells may be an effective means to inhibit macrophage-mediated tubulointerstitial injury without causing systemic immunosuppression.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11509677     DOI: 10.1093/ndt/16.suppl_5.3

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  49 in total

1.  Chronic sphingosine 1-phosphate 1 receptor activation attenuates early-stage diabetic nephropathy independent of lymphocytes.

Authors:  Alaa S Awad; Michael D Rouse; Konstantine Khutsishvili; Liping Huang; W Kline Bolton; Kevin R Lynch; Mark D Okusa
Journal:  Kidney Int       Date:  2011-02-02       Impact factor: 10.612

2.  In situ glomerular expression of activated NF-kappaB in human lupus nephritis and other non-proliferative proteinuric glomerulopathy.

Authors:  Ling Zheng; Raja Sinniah; Stephen I-Hong Hsu
Journal:  Virchows Arch       Date:  2005-10-05       Impact factor: 4.064

Review 3.  Inflammatory processes in renal fibrosis.

Authors:  Xiao-Ming Meng; David J Nikolic-Paterson; Hui Yao Lan
Journal:  Nat Rev Nephrol       Date:  2014-07-01       Impact factor: 28.314

Review 4.  Mediators of inflammation in acute kidney injury.

Authors:  Ali Akcay; Quocan Nguyen; Charles L Edelstein
Journal:  Mediators Inflamm       Date:  2010-02-21       Impact factor: 4.711

Review 5.  New molecular insights in diabetic nephropathy.

Authors:  Ionel Alexandru Checheriţă; Gina Manda; Mihai Eugen Hinescu; Ileana Peride; Andrei Niculae; Ştefana Bîlha; Angelica Grămăticu; Luminiţa Voroneanu; Adrian Covic
Journal:  Int Urol Nephrol       Date:  2016-01-12       Impact factor: 2.370

6.  Requirement for TLR2 in the development of albuminuria, inflammation and fibrosis in experimental diabetic nephropathy.

Authors:  Jin Ma; Huiling Wu; Cathy Y Zhao; Usha Panchapakesan; Carol Pollock; Steven J Chadban
Journal:  Int J Clin Exp Pathol       Date:  2014-01-15

7.  The role of mast cells in acute tubulo-interstitial nephritis with uveitis.

Authors:  Shuji Kondo; Shoji Kagami; Maki Shimizu; Akiko Kitamura; Maki Urushihara; Nobuo Satake; Keisuke Izumi; Yasuhiro Kuroda
Journal:  Eur J Pediatr       Date:  2003-05-06       Impact factor: 3.183

8.  Human macrophages kill human mesangial cells by Fas-L-induced apoptosis when triggered by antibody via CD16.

Authors:  J J Boyle
Journal:  Clin Exp Immunol       Date:  2004-09       Impact factor: 4.330

9.  A molecular signature of proteinuria in glomerulonephritis.

Authors:  Heather N Reich; David Tritchler; Daniel C Cattran; Andrew M Herzenberg; Felix Eichinger; Anissa Boucherot; Anna Henger; Celine C Berthier; Viji Nair; Clemens D Cohen; James W Scholey; Matthias Kretzler
Journal:  PLoS One       Date:  2010-10-18       Impact factor: 3.240

10.  Selective CCR2-targeted macrophage depletion ameliorates experimental mesangioproliferative glomerulonephritis.

Authors:  L M McIntosh; J L Barnes; V L Barnes; J R McDonald
Journal:  Clin Exp Immunol       Date:  2008-11-25       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.